I warned them that Ventilating the patients carte blanche was killing people, I am no ventilatory expert but the ventilator was another of the misleading guidance Trump got; ventilators killed people

You will come to learn one day that we killed thousands with the ventilators, it did not help them, it harmed them, 80% or more of coronavirus patients placed on the machines in New York City died

You may not like how blunt I am and the topics I WANT to share on, but I want to share information I think you were not made privy to. The discussion on how devastating the ventilator was for the COVID patient must be had and it will be had, at some point. The ventilator was not what it was sold as, it was an ‘angel of death’.

Cuomo was right to question it, like him or not, he was right…

Trump was mislead and this is where him not being a scientist, wanting anything that could work for he wanted to help his people and fix this, wanted to be seen fixing it, and trusting the demons around him like Fauci et al. Now you look back and recognize these people are among the most inept people around, they harmed and killed people with their polices, from lockdowns all the way to vaccine.

Experts estimate 40-50% of ventilated patients die, regardless of their disease. Around the world, between 66 and 86% of all “Covid patients” put on ventilators died.

“NEW YORK (AP) — As health officials around the world push to get more ventilators to treat coronavirus patients, some doctors are moving away from using the breathing machines when they can.

The reason: Some hospitals have reported unusually high death rates for coronavirus patients on ventilators, and some doctors worry that the machines could be harming certain patients.” https://apnews.com/article/health-us-news-ap-top-news-international-news-virus-outbreak-8ccd325c2be9bf454c2128dcb7bd616d

“But the ventilator also marks a crisis point in a patient's COVID-19 course, and questions are now being raised as to whether the machines can cause harm, too.

Many who go on a ventilator die, and those who survive likely will face ongoing breathing problems caused by either the machine or the damage done by the virus.

The problem is that the longer people are on ventilation, the more likely they are to suffer complications related to machine-assisted breathing.

Recognizing this, some intensive care units have started to delay putting a COVID-19 patient on a ventilator to the last possible moment, when it is truly a life-or-death decision, said Dr. Udit Chaddha, an interventional pulmonologist with Mount Sinai Hospital in New York City.” https://www.webmd.com/lung/news/20200415/ventilators-helping-or-harming-covid-19-patients#1

Ventilator-associated pneumonia (VAP) continues to complicate the course of 8 to 28% of patients receiving mechanical ventilation (MV). In contrast to infections of more frequently involved organs (e.g., urinary tract and skin), for which mortality is low, ranging from 1 to 4%, the mortality rate for VAP ranges from 24 to 50% and can reach 76% in some specific settings or when lung infection is caused by high-risk pathogens. The predominant organisms responsible for infection are Staphylococcus aureus, Pseudomonas aeruginosa, and Enterobacteriaceae, but etiologic agents widely differ according to the population of patients in an intensive care unit, duration of hospital stay, and prior antimicrobial therapy. Because appropriate antimicrobial treatment of patients with VAP significantly improves outcome, more rapid identification of infected patients and accurate selection of antimicrobial agents represent important clinical goals. Our personal bias is that using bronchoscopic techniques to obtain protected brush and bronchoalveolar lavage specimens from the affected area in the lung permits physicians to devise a therapeutic strategy that is superior to one based only on clinical evaluation. When fiberoptic bronchoscopy is not available to physicians treating patients clinically suspected of having VAP, we recommend using either a simplified nonbronchoscopic diagnostic procedure or following a strategy in which decisions regarding antibiotic therapy are based on a clinical score constructed from seven variables. Selection of the initial antimicrobial therapy should be based on predominant flora responsible for VAP at each institution, clinical setting, information provided by direct examination of pulmonary secretions, and intrinsic antibacterial activities of antimicrobial agents and their pharmacokinetic characteristics. Further trials will be needed to clarify the optimal duration of treatment and the circumstances in which monotherapy can be safely used. https://www.atsjournals.org/doi/full/10.1164/ajrccm.165.7.2105078